The VA Medicinal Cannabis Research Act is intended to urge the Secretary of Veterans Affairs (VA) to investigate the potential benefits and effects of the cannabis.

Under the legislation, the Senators direct the VA on a double-blind, randomised, controlled trial to evaluate the medicinal cannabis’ effectiveness in mitigating symptoms of chronic pain and/or PTSD.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The trial will also be designed to study effects on mood, social functioning or other substance use.

It may additionally include assessment of the impact of the cannabis on pulmonary function, cardiovascular events, certain cancers, mania and cognitive effects, among others.

Tester said: “The VA needs to listen to the growing number of veterans who have already found success in medicinal cannabis in easing their pain and other symptoms.

“Our bill will make sure the VA takes proactive steps to explore medicinal cannabis as a safe and effective alternative to opioids for veterans suffering from injuries or illness received in the line of duty.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The clinical trial is set to study a variety of cannabis types such as full plants and extracts, a minimum of three different strains and various delivery approaches.

Furthermore, the VA may choose to conduct a long-term observational study in individuals participating in the trial.

Tester and Sullivan along with Representatives Phil Roe and Tim Walz initially wrote to the US Department of Veterans Affairs in August last year, highlighting the need for a trial to understand medicinal cannabis use.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact